FDA reviewers are not impressed with data on "female Viagra"

06/16/2010 | CNN

Flibanserin, Boehringer Ingelheim's drug candidate for sexual dysfunction in women, caused only slight improvement in postmenopausal women with hypoactive sexual desire disorder, FDA reviewers reported. A Boehringer official said the firm continues to believe in clinical data demonstrating the safety and efficacy of flibanserin "in balancing the chemicals in the brain linked to sexual desire." The drug will be reviewed by an FDA panel Friday.

View Full Article in:

CNN

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ